## **Product** Data Sheet

# Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA

Cat. No.: HY-P2300A  $C_{26}H_{35}F_{3}N_{8}O_{9}S$ Molecular Formula:


Molecular Weight: 692.66 Target: Integrin Pathway: Cytoskeleton

Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years -20°C 1 year

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light, under nitrogen)



## SOLVENT & SOLUBILITY

In Vitro

Storage:

H<sub>2</sub>O: 5 mg/mL (7.22 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.4437 mL	7.2185 mL	14.4371 mL
	5 mM	0.2887 mL	1.4437 mL	2.8874 mL
	10 mM			

Please refer to the solubility information to select the appropriate solvent.

## **BIOLOGICAL ACTIVITY**

Description	Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to $\alpha\nu\beta3$ , can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors <sup>[1]</sup> .

	(ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors <sup>[1]</sup> .
IC <sub>50</sub> & Target	ανβ3
In Vitro	Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA (0.5 mM; 24 h) down-regulates the transcription factors Oct 4, Sox 2 and Nanog of mESCs [1].  Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA (0.5 mM) inhibits integrin gene expression mESC-col I (type I collagen) constructs <sup>[1]</sup> .  Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA (0.5 mM)-treated mESC leads to the formation of aggregates and detachment from the surface <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA (0.5 mM, 24 h)-treated mESCs in the presence/absence of Leukemia inhibitory factor (LIF)

(injected in both thighs) generated teratomas in severe combined immunodeficiency (SCID) mice, which indicates that the process of mESC tumor formation in vivo is dependent on integrin interaction  $^{[1]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Hazenbiller O, et al. Reduction of pluripotent gene expression in murine embryonic stem cells exposed to mechanical loading or Cyclo RGD peptide. BMC Cell Biol. 2017 Nov 14;18(1):32.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com